ABEO ▲ +1.4% - Abeona Therapeutics Inc. $ABEO - Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) Abeona Therapeutics rose 1.4% following Ultragenyx's U.S. FDA approval of FAYUVI, a gene therapy for Sanfilippo Syndrome Type A. The approval validates the therapeutic approach in a rare genetic disorder and may signal positive momentum for the broader gene therapy sector in which Abeona operates. 18-SEP-2026 07:30 AM ET